Free Trial
→ Feds Just Admitted It—They Can Take Your Cash (From Priority Gold) (Ad) Buy ALLO Stock  Free ALLO Stock Alerts

Allogene Therapeutics (ALLO) Financials

Allogene Therapeutics logo
$1.40 -0.22 (-13.27%)
As of 03:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Allogene Therapeutics

Annual Income Statements for Allogene Therapeutics

This table shows Allogene Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -340 -327 -258
Consolidated Net Income / (Loss)		 -340 -327 -258
Net Income / (Loss) Continuing Operations		 -340 -327 -258
Total Pre-Tax Income 		-340 -327 -257
Total Operating Income		 -336 -328 -273
Total Gross Profit		 0.16 0.10 0.02
Total Revenue		 0.16 0.10 0.02
Operating Revenue		 0.16 0.10 0.02
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 336 328 273
Selling, General & Admin Expense		 79 72 65
Research & Development Expense		 256 243 192
Impairment Charge		 0.00 13 16
Total Other Income / (Expense), net		 -4.88 0.47 16
Interest Expense		 - 0.00 0.18
Interest & Investment Income		 4.57 18 20
Other Income / (Expense), net		 -9.44 -18 -3.92
Income Tax Expense		 - 0.00 0.44
Basic Earnings per Share		 ($2.38) ($2.09) ($1.32)
Weighted Average Basic Shares Outstanding		 143.15M 156.93M 194.81M
Diluted Earnings per Share		 ($2.38) ($2.09) ($1.32)
Weighted Average Diluted Shares Outstanding		 143.15M 156.93M 194.81M
Weighted Average Basic & Diluted Shares Outstanding		 144.50M 169.09M 217.26M
Cash Dividends to Common per Share		 $0.00 $0.00 $0.00

Quarterly Income Statements for Allogene Therapeutics

This table shows Allogene Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -83 -103 -100 -79 -62 -86 -65 -66 -66 -60
Consolidated Net Income / (Loss)		 -83 -103 -100 -79 -62 -86 -65 -66 -66 -60
Net Income / (Loss) Continuing Operations		 -83 -103 -100 -79 -62 -86 -65 -66 -66 -60
Total Pre-Tax Income 		-83 -103 -100 -79 -62 -86 -65 -66 -66 -59
Total Operating Income		 -82 -96 -99 -81 -63 -85 -70 -71 -72 -60
Total Operating Expenses		 83 96 99 81 63 85 70 71 72 60
Selling, General & Admin Expense		 19 21 19 19 17 17 17 16 16 16
Research & Development Expense		 64 75 80 62 46 55 52 50 45 45
Total Other Income / (Expense), net		 -0.66 -6.17 -0.88 1.31 0.71 -0.67 4.50 5.07 5.48 0.99
Other Income / (Expense), net		 -1.66 -9.42 -0.88 -2.47 -5.50 -8.99 4.50 0.09 -1.12 -7.39
Basic Earnings per Share		 ($0.58) ($0.72) ($0.69) ($0.54) ($0.37) ($0.49) ($0.38) ($0.35) ($0.32) ($0.27)
Weighted Average Basic Shares Outstanding		 143.66M 143.15M 144.56M 146.80M 167.65M 156.93M 169.13M 190.03M 209.19M 194.81M
Diluted Earnings per Share		 ($0.58) ($0.72) ($0.69) ($0.54) ($0.37) ($0.49) ($0.38) ($0.35) ($0.32) ($0.27)
Weighted Average Diluted Shares Outstanding		 143.66M 143.15M 144.56M 146.80M 167.65M 156.93M 169.13M 190.03M 209.19M 194.81M
Weighted Average Basic & Diluted Shares Outstanding		 144.21M 144.50M 145.84M 167.63M 168.28M 169.09M 170.85M 209.11M 209.67M 217.26M

Annual Cash Flow Statements for Allogene Therapeutics

This table details how cash moves in and out of Allogene Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -111 21 -7.94
Net Cash From Operating Activities		 -221 -238 -200
Net Cash From Continuing Operating Activities		 -221 -238 -200
Net Income / (Loss) Continuing Operations		 -340 -327 -258
Consolidated Net Income / (Loss)		 -340 -327 -258
Depreciation Expense		 14 14 14
Non-Cash Adjustments To Reconcile Net Income		 102 91 62
Changes in Operating Assets and Liabilities, net		 3.90 -15 -18
Net Cash From Investing Activities		 106 163 76
Net Cash From Continuing Investing Activities		 106 163 76
Purchase of Property, Plant & Equipment		 -5.19 -1.52 -0.69
Purchase of Investments		 -248 -439 -361
Sale and/or Maturity of Investments		 359 603 438
Net Cash From Financing Activities		 2.95 96 117
Net Cash From Continuing Financing Activities		 2.95 96 117
Issuance of Common Equity		 2.95 96 114
Other Financing Activities, net		 - 0.00 2.28

Quarterly Cash Flow Statements for Allogene Therapeutics

This table details how cash moves in and out of Allogene Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -22 -12 48 45 -86 14 -32 120 -119 24
Net Cash From Operating Activities		 -48 -62 -67 -62 -56 -54 -56 -64 -44 -37
Net Cash From Continuing Operating Activities		 -48 -62 -67 -62 -56 -54 -56 -64 -44 -37
Net Income / (Loss) Continuing Operations		 -83 -103 -100 -79 -62 -86 -65 -66 -66 -60
Consolidated Net Income / (Loss)		 -83 -103 -100 -79 -62 -86 -65 -66 -66 -60
Depreciation Expense		 3.86 3.07 3.51 3.64 3.57 3.48 3.56 3.64 3.21 3.23
Non-Cash Adjustments To Reconcile Net Income		 24 26 22 18 22 28 9.99 16 23 13
Changes in Operating Assets and Liabilities, net		 7.79 11 7.42 -4.36 -19 0.93 -4.44 -17 -4.35 7.05
Net Cash From Investing Activities		 25 50 113 17 -34 67 22 75 -76 55
Net Cash From Continuing Investing Activities		 25 50 113 17 -34 67 22 75 -76 55
Purchase of Property, Plant & Equipment		 -0.22 -1.69 -1.04 -0.29 -0.01 -0.18 -0.01 - -0.43 -0.26
Purchase of Investments		 -49 -48 -35 -135 -199 -69 -81 -43 -191 -47
Sale and/or Maturity of Investments		 75 99 149 153 165 136 103 117 115 102
Net Cash From Financing Activities		 1.07 0.05 1.73 90 4.29 0.16 1.65 109 0.68 5.74
Net Cash From Continuing Financing Activities		 1.07 0.05 1.73 90 4.29 0.16 1.65 109 0.68 5.74
Issuance of Common Equity		 1.07 0.05 1.73 90 4.29 0.16 1.65 106 0.68 5.74

Annual Balance Sheets for Allogene Therapeutics

This table presents Allogene Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 822 643 549
Total Current Assets		 529 459 303
Cash & Equivalents		 62 83 75
Short-Term Investments		 455 366 217
Prepaid Expenses		 12 10 11
Plant, Property, & Equipment, net		 113 99 86
Total Noncurrent Assets		 180 84 159
Long-Term Investments		 76 3.65 81
Other Noncurrent Operating Assets		 103 81 79
Total Liabilities & Shareholders' Equity		 822 643 549
Total Liabilities		 155 131 127
Total Current Liabilities		 54 37 36
Accounts Payable		 14 5.90 5.39
Accrued Expenses		 40 31 30
Total Noncurrent Liabilities		 101 94 91
Other Noncurrent Operating Liabilities		 101 94 91
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 667 512 422
Total Preferred & Common Equity		 667 512 422
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 667 512 422
Common Stock		 1,912 2,075 2,242
Retained Earnings		 -1,235 -1,562 -1,820
Accumulated Other Comprehensive Income / (Loss)		 -9.93 -0.96 -0.09

Quarterly Balance Sheets for Allogene Therapeutics

This table presents Allogene Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 888 747 771 712 586 647 589
Total Current Assets		 569 481 502 473 395 457 304
Cash & Equivalents		 74 110 155 69 51 171 51
Short-Term Investments		 478 361 337 396 334 274 240
Prepaid Expenses		 17 10 10 7.95 11 12 13
Plant, Property, & Equipment, net		 114 110 106 103 96 92 89
Total Noncurrent Assets		 204 156 162 136 95 98 196
Long-Term Investments		 99 54 62 38 15 1.13 112
Other Noncurrent Operating Assets		 105 102 100 99 80 97 84
Total Liabilities & Shareholders' Equity		 888 747 771 712 586 647 589
Total Liabilities		 148 155 148 129 125 132 125
Total Current Liabilities		 49 60 55 38 31 37 33
Accounts Payable		 11 15 10 6.21 5.78 13 5.51
Accrued Expenses		 37 45 44 31 25 24 27
Total Noncurrent Liabilities		 99 95 93 92 94 95 93
Other Noncurrent Operating Liabilities		 99 95 93 92 94 95 93
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 740 592 623 583 461 515 464
Total Preferred & Common Equity		 740 592 623 583 461 515 464
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 740 592 623 583 461 515 464
Common Stock		 1,894 1,933 2,039 2,060 2,090 2,209 2,223
Retained Earnings		 -1,141 -1,335 -1,413 -1,474 -1,627 -1,694 -1,760
Accumulated Other Comprehensive Income / (Loss)		 -13 -5.93 -3.85 -2.41 -0.93 -0.78 0.16

Annual Metrics and Ratios for Allogene Therapeutics

This table displays calculated financial ratios and metrics derived from Allogene Therapeutics' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 -99.86% -39.10% -76.84%
EBITDA Growth		 -90.80% -0.21% 20.49%
EBIT Growth		 -87.73% -0.17% 19.81%
NOPAT Growth		 -86.21% 2.32% 16.64%
Net Income Growth		 -86.99% 3.86% 21.29%
EPS Growth		 -77.61% 12.18% 36.84%
Operating Cash Flow Growth		 -19.32% -7.81% 15.75%
Free Cash Flow Firm Growth		 -32.49% 2.80% 16.57%
Invested Capital Growth		 -14.53% -18.06% -18.13%
Revenue Q/Q Growth		 -99.79% -43.79% -48.84%
EBITDA Q/Q Growth		 -49.03% 3.55% 8.98%
EBIT Q/Q Growth		 -45.34% 3.30% 8.65%
NOPAT Q/Q Growth		 -41.36% 3.35% 8.27%
Net Income Q/Q Growth		 -43.21% 4.90% 9.12%
EPS Q/Q Growth		 -44.24% 9.91% 14.29%
Operating Cash Flow Q/Q Growth		 -8.17% 3.41% 7.83%
Free Cash Flow Firm Q/Q Growth		 -35.30% 5.52% 4.45%
Invested Capital Q/Q Growth		 -17.48% -25.19% -18.77%
Profitability Metrics		 - - -
Gross Margin		 100.00% 100.00% 100.00%
EBITDA Margin		 -211,977.56% -348,813.68% -1,197,636.36%
Operating Margin		 -215,087.18% -344,986.32% -1,241,813.64%
EBIT Margin		 -221,141.03% -363,760.00% -1,259,631.82%
Profit (Net Income) Margin		 -218,214.10% -344,489.47% -1,170,863.64%
Tax Burden Percent		 100.00% 100.00% 100.17%
Interest Burden Percent		 98.68% 94.70% 92.79%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -296.16% -345.03% -351.15%
ROIC Less NNEP Spread (ROIC-NNEP)		 -281.43% -326.32% -335.08%
Return on Net Nonoperating Assets (RNNOA)		 253.40% 289.52% 296.02%
Return on Equity (ROE)		 -42.76% -55.51% -55.13%
Cash Return on Invested Capital (CROIC)		 -280.49% -325.17% -331.21%
Operating Return on Assets (OROA)		 -36.85% -47.20% -46.51%
Return on Assets (ROA)		 -36.36% -44.70% -43.24%
Return on Common Equity (ROCE)		 -42.76% -55.51% -55.13%
Return on Equity Simple (ROE_SIMPLE)		 -51.05% -63.89% -61.01%
Net Operating Profit after Tax (NOPAT)		 -235 -229 -191
NOPAT Margin		 -150,561.03% -241,490.42% -869,269.55%
Net Nonoperating Expense Percent (NNEP)		 -14.73% -18.71% -16.08%
Return On Investment Capital (ROIC_SIMPLE)		 - -44.79% -45.30%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 50,836.54% 75,445.26% 296,386.36%
R&D to Revenue		 164,350.64% 255,698.95% 874,086.36%
Operating Expenses to Revenue		 215,187.18% 345,086.32% 1,241,913.64%
Earnings before Interest and Taxes (EBIT)		 -345 -346 -277
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -331 -331 -263
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.36 1.05 1.06
Price to Tangible Book Value (P/TBV)		 1.36 1.05 1.06
Price to Revenue (P/Rev)		 5,814.63 5,685.98 20,300.07
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.29 1.47 1.50
Enterprise Value to Revenue (EV/Rev)		 2,008.29 924.49 3,338.75
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -0.90 -0.89 -0.88
Leverage Ratio		 1.18 1.24 1.28
Compound Leverage Factor		 1.16 1.18 1.18
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 0.72 -1.91 -3.61
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 9.84 12.38 8.54
Quick Ratio		 9.63 12.10 8.23
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -222 -216 -180
Operating Cash Flow to CapEx		 -4,248.10% -15,681.60% -28,861.67%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -996.57
Operating Cash Flow to Interest Expense		 0.00 0.00 -1,106.63
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -1,110.46
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 73 60 49
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -12 -13 -11
Enterprise Value (EV)		 313 88 73
Market Capitalization		 907 540 447
Book Value per Share		 $4.62 $3.04 $2.01
Tangible Book Value per Share		 $4.62 $3.04 $2.01
Total Capital		 667 512 422
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -594 -452 -373
Capital Expenditures (CapEx)		 5.19 1.52 0.69
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -42 -27 -25
Debt-free Net Working Capital (DFNWC)		 475 422 268
Net Working Capital (NWC)		 475 422 268
Net Nonoperating Expense (NNE)		 106 98 66
Net Nonoperating Obligations (NNO)		 -594 -452 -373
Total Depreciation and Amortization (D&A)		 14 14 14
Debt-free, Cash-free Net Working Capital to Revenue		 -27,066.67% -28,064.21% -111,877.27%
Debt-free Net Working Capital to Revenue		 304,548.72% 444,248.42% 1,217,559.09%
Net Working Capital to Revenue		 304,548.72% 444,248.42% 1,217,559.09%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.09) ($1.32)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 156.93M 194.81M
Adjusted Diluted Earnings per Share		 $0.00 ($2.09) ($1.32)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 156.93M 194.81M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 169.09M 217.26M
Normalized Net Operating Profit after Tax (NOPAT)		 -235 -220 -180
Normalized NOPAT Margin		 -150,561.03% -231,730.95% -819,260.91%
Pre Tax Income Margin		 -218,214.10% -344,489.47% -1,168,850.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 -1,531.04
NOPAT to Interest Expense		 0.00 0.00 -1,056.57
EBIT Less CapEx to Interest Expense		 0.00 0.00 -1,534.88
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -1,060.41
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Allogene Therapeutics

This table displays calculated financial ratios and metrics derived from Allogene Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% -99.87% -50.82% 0.00% 0.00% -77.89% -26.67% -100.00% -100.00% 0.00%
EBITDA Growth		 -6.57% -1,827.90% -26.66% -11.12% 19.14% 11.85% 36.30% 14.70% -7.35% 28.67%
EBIT Growth		 -8.34% -6,298.95% -25.19% -10.53% 18.61% 11.12% 34.98% 14.05% -6.43% 27.87%
NOPAT Growth		 -6.20% -4,053.32% -23.88% -5.15% 23.63% 11.77% 29.86% 11.31% -13.93% 28.93%
Net Income Growth		 -6.35% -119,436.05% -25.19% -5.94% 25.09% 16.42% 34.98% 16.25% -6.43% 30.12%
EPS Growth		 -1.75% -7,300.00% -23.21% -3.85% 36.21% 31.94% 44.93% 35.19% 13.51% 44.90%
Operating Cash Flow Growth		 2.50% -36.67% 2.34% -45.44% -16.53% 13.51% 16.12% -2.80% 20.56% 31.67%
Free Cash Flow Firm Growth		 29.56% -37.57% 63.14% 60.14% 36.46% 15.83% -50.01% -105.77% 14.16% 32.11%
Invested Capital Growth		 -1.93% -14.53% -37.78% -31.64% -9.61% -18.06% -8.55% 1.21% -24.60% -18.13%
Revenue Q/Q Growth		 0.00% 0.00% -68.42% -26.67% 0.00% -4.55% -48.84% -100.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -12.41% -28.05% 6.18% 17.72% 18.20% -39.59% 32.92% -10.18% -2.94% 7.24%
EBIT Q/Q Growth		 -12.05% -25.82% 5.58% 16.96% 17.49% -37.39% 31.63% -9.76% -2.18% 6.89%
NOPAT Q/Q Growth		 -7.70% -16.94% -2.73% 18.72% 21.78% -35.10% 18.36% -2.77% -0.48% 15.72%
Net Income Q/Q Growth		 -11.18% -23.43% 2.59% 20.74% 21.39% -37.71% 25.07% -2.09% 0.10% 9.58%
EPS Q/Q Growth		 -11.54% -24.14% 4.17% 21.74% 31.48% -32.43% 22.45% 7.89% 8.57% 15.63%
Operating Cash Flow Q/Q Growth		 -12.05% -30.30% -7.32% 7.18% 10.23% 3.28% -4.08% -13.76% 30.62% 16.81%
Free Cash Flow Firm Q/Q Growth		 9.65% 1.60% 48.08% 13.65% -44.04% -30.33% 7.49% -18.45% 39.91% -3.08%
Invested Capital Q/Q Growth		 -11.53% -17.48% -8.16% 1.97% 16.97% -25.19% 2.50% 12.85% -12.87% -18.77%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% -108,221.05% -321,536.67% -360,759.09% -295,090.91% -431,547.62% -279,295.45% 0.00% 0.00% 0.00%
Operating Margin		 0.00% -101,537.89% -330,306.67% -366,090.91% -286,345.45% -405,280.95% -315,927.27% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% -111,450.53% -333,226.67% -377,318.18% -311,327.27% -448,104.76% -295,454.55% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -108,030.53% -333,226.67% -360,145.45% -283,122.73% -408,466.67% -295,454.55% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.74%
Interest Burden Percent		 98.81% 96.93% 100.00% 95.45% 90.94% 91.15% 100.00% 93.01% 90.94% 87.66%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -139.81% -330.29% -446.94% -401.74% -405.33% -299.43% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -134.91% -325.48% -443.30% -398.59% -400.32% -295.89% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 121.47% 286.13% 390.86% 347.78% 355.17% 259.80% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -18.34% -44.16% -56.08% -53.96% -50.16% -39.62% 0.00% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)		 -183.80% -280.49% -237.12% -260.22% -271.40% -325.17% -315.87% -295.02% -268.86% -331.21%
Operating Return on Assets (OROA)		 0.00% -18.57% -48.67% -64.55% -65.77% -58.14% -38.56% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -18.00% -48.67% -61.61% -59.81% -53.00% -38.56% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -18.34% -44.16% -56.08% -53.96% -50.16% -39.62% 0.00% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -32.12% 0.00% -60.87% -58.59% -59.01% 0.00% -63.35% -54.25% -61.12% 0.00%
Net Operating Profit after Tax (NOPAT)		 -58 -68 -69 -56 -44 -60 -49 -50 -50 -42
NOPAT Margin		 0.00% -71,076.53% -231,214.67% -256,263.64% -200,441.82% -283,696.67% -221,149.09% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.32% -4.90% -4.81% -3.64% -3.15% -5.01% -3.53% -3.27% -3.54% -4.26%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -11.63% - - - -10.03%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 22,107.37% 62,946.67% 84,200.00% 77,459.09% 82,019.05% 78,486.36% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 79,388.42% 267,460.00% 281,990.91% 208,986.36% 260,290.48% 237,540.91% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 101,495.79% 330,406.67% 366,190.91% 286,445.45% 405,380.95% 316,027.27% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -84 -106 -100 -83 -68 -94 -65 -71 -73 -68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -80 -103 -96 -79 -65 -91 -61 -68 -70 -65
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.10 1.36 1.21 1.16 0.91 1.05 1.64 0.77 1.26 1.06
Price to Tangible Book Value (P/TBV)		 2.10 1.36 1.21 1.16 0.91 1.05 1.64 0.77 1.26 1.06
Price to Revenue (P/Rev)		 20.49 5,814.63 5,710.54 4,930.84 3,144.23 5,685.98 8,687.83 6,124.44 13,616.56 20,300.07
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 10.18 4.29 2.81 2.49 0.35 1.47 5.80 0.00 3.02 1.50
Enterprise Value to Revenue (EV/Rev)		 11.90 2,008.29 1,509.45 1,159.01 167.67 924.49 4,090.35 0.00 4,235.52 3,338.75
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.90 -0.90 -0.88 -0.88 -0.87 -0.89 -0.88 -0.88 -0.87 -0.88
Leverage Ratio		 1.15 1.18 1.18 1.21 1.21 1.24 1.27 1.25 1.24 1.28
Compound Leverage Factor		 1.14 1.14 1.18 1.15 1.10 1.13 1.27 1.16 1.13 1.12
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 4.99 1.68 0.50 0.71 -0.01 -0.62 0.12 -1.44 -1.23 -2.35
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 11.64 9.84 8.08 9.18 12.58 12.38 12.80 12.25 9.35 8.54
Quick Ratio		 11.30 9.63 7.91 8.99 12.37 12.10 12.46 11.92 8.95 8.23
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -56 -55 -29 -25 -36 -46 -43 -51 -31 -31
Operating Cash Flow to CapEx		 -21,369.96% -3,669.98% -6,438.55% -21,478.13% -462,750.00% -29,672.38% -698,737.50% 0.00% -10,283.22% -14,279.38%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -305.43 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -441.15 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -445.44 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.63 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 89 73 67 68 80 60 61 69 60 49
Invested Capital Turnover		 0.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -1.75 -12 -41 -32 -8.52 -13 -5.74 0.83 -20 -11
Enterprise Value (EV)		 902 313 189 170 28 88 356 -48 182 73
Market Capitalization		 1,553 907 714 725 531 540 756 398 586 447
Book Value per Share		 $5.15 $4.62 $4.10 $4.27 $3.48 $3.04 $2.73 $3.01 $2.22 $2.01
Tangible Book Value per Share		 $5.15 $4.62 $4.10 $4.27 $3.48 $3.04 $2.73 $3.01 $2.22 $2.01
Total Capital		 740 667 592 623 583 512 461 515 464 422
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -651 -594 -525 -554 -503 -452 -400 -446 -403 -373
Capital Expenditures (CapEx)		 0.22 1.69 1.04 0.29 0.01 0.18 0.01 0.00 0.43 0.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -32 -42 -49 -45 -30 -27 -20 -25 -20 -25
Debt-free Net Working Capital (DFNWC)		 520 475 422 447 436 422 364 420 272 268
Net Working Capital (NWC)		 520 475 422 447 436 422 364 420 272 268
Net Nonoperating Expense (NNE)		 25 35 31 23 18 26 16 16 16 18
Net Nonoperating Obligations (NNO)		 -651 -594 -525 -554 -503 -452 -400 -446 -403 -373
Total Depreciation and Amortization (D&A)		 3.86 3.07 3.51 3.64 3.57 3.48 3.56 3.64 3.21 3.23
Debt-free, Cash-free Net Working Capital to Revenue		 -42.27% -27,066.67% -39,475.20% -30,327.89% -17,566.27% -28,064.21% -23,436.78% -38,167.69% -45,860.47% -111,877.27%
Debt-free Net Working Capital to Revenue		 686.22% 304,548.72% 337,504.00% 304,340.14% 257,880.47% 444,248.42% 418,931.03% 645,875.38% 632,195.35% 1,217,559.09%
Net Working Capital to Revenue		 686.22% 304,548.72% 337,504.00% 304,340.14% 257,880.47% 444,248.42% 418,931.03% 645,875.38% 632,195.35% 1,217,559.09%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.58) ($0.72) ($0.68) ($0.53) ($0.37) ($0.49) ($0.38) ($0.35) ($0.32) ($0.27)
Adjusted Weighted Average Basic Shares Outstanding		 143.66M 143.15M 144.56M 146.80M 167.65M 156.93M 169.13M 190.03M 209.19M 194.81M
Adjusted Diluted Earnings per Share		 ($0.58) ($0.72) ($0.68) ($0.53) ($0.37) ($0.49) ($0.38) ($0.35) ($0.32) ($0.27)
Adjusted Weighted Average Diluted Shares Outstanding		 143.66M 143.15M 144.56M 146.80M 167.65M 156.93M 169.13M 190.03M 209.19M 194.81M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 144.21M 144.50M 145.84M 167.63M 168.28M 169.09M 170.85M 209.11M 209.67M 217.26M
Normalized Net Operating Profit after Tax (NOPAT)		 -58 -68 -69 -56 -44 -60 -49 -47 -43 -42
Normalized NOPAT Margin		 0.00% -71,076.53% -231,214.67% -256,263.64% -200,441.82% -283,696.67% -221,149.09% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -108,030.53% -333,226.67% -360,145.45% -283,122.73% -408,466.67% -295,454.55% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -728.98 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -502.42 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -733.27 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -506.71 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Allogene Therapeutics' Financials

When does Allogene Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Allogene Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Allogene Therapeutics' net income changed over the last 2 years?

Allogene Therapeutics' net income appears to be on a downward trend, with a most recent value of -$257.59 million in 2024, falling from -$340.41 million in 2022. The previous period was -$327.27 million in 2023. See where experts think Allogene Therapeutics is headed by visiting Allogene Therapeutics' forecast page.

What is Allogene Therapeutics's operating income?
Allogene Therapeutics's total operating income in 2024 was -$273.20 million, based on the following breakdown:
  • Total Gross Profit: $22 thousand
  • Total Operating Expenses: $273.22 million
How has Allogene Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Allogene Therapeutics' total revenue changed from $156 thousand in 2022 to $22 thousand in 2024, a change of -85.9%.

How much debt does Allogene Therapeutics have?

Allogene Therapeutics' total liabilities were at $126.53 million at the end of 2024, a 3.1% decrease from 2023, and a 18.2% decrease since 2022.

How much cash does Allogene Therapeutics have?

In the past 2 years, Allogene Therapeutics' cash and equivalents has ranged from $61.90 million in 2022 to $83.16 million in 2023, and is currently $75.22 million as of their latest financial filing in 2024.

How has Allogene Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Allogene Therapeutics' book value per share changed from 4.62 in 2022 to 2.01 in 2024, a change of -56.5%.


Related Companies

This page (NASDAQ:ALLO) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...
Colonial Metals | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...
Golden Portfolio | Sponsored
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Paradigm Press | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...
Crypto 101 Media | Sponsored
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...
Brownstone Research | Sponsored